Confirm delete?

Bertin Bioreagent
logo

Search

Contact Us

CYP2B6 (human) MS2Plex® assay kit

  • Zoom
    CYP2B6 (human) MS2Plex® assay kit
  • CYP2B6 (human) MS2Plex® assay kit
Cat No: T05009
Assays - Ms2Plex Kits - Human Cyp450S
MS2Plex
Price is excluding VAT and does not include packaging neither shipping

Human CYP450s Assays Xenobiotic biotransformation is the principal mechanism for maintaining homeostasis during organism exposure to foreign molecules such as drugs. It is accomplished by a limited number of enzymes with broad substrate specificities. ...

More
: 24 dtn

This article is not for sale online.
Contact us for more information about this article.

Territorial Availability: Available worldwide directly through Bertin Technologies or your local distributor
Technical Warning: Human CYP450s Kits
Product Overview:
Human CYP450s Assays Xenobiotic biotransformation is the principal mechanism for maintaining homeostasis during organism exposure to foreign molecules such as drugs. It is accomplished by a limited number of enzymes with broad substrate specificities. Reactions catalyzed by xenobiotic-biotransforming enzymes are divided into two groups, called phase I and phase II, leading to an increase in hydrophilicity of xenobiotic, greatly enhancing their elimination. Among the phase I biotransforming enzymes, cytochromes P450 (CYP450) rank first in terms of oxidation catalytic versatility and the broad number of xenobiotics they detoxify or activate to reactive intermediates, that may or may not be taken in charge by phase II enzymes. Being the major elimination route for many drugs, CYP450 enzymes play a very important role in the detoxication of xenobiotics, but may also lead to toxic or tumorigenic metabolites.
Size: 24 dtn
Shipping: Dry ice
Stability: Store at -80degrees; shelf life 6 months maximum after production
Application Media: Microsomes, tissues extracts, cell membrane fractions
Sample volume: 50 μg of total protein
Detection Limit: 0.75 fmol/μg of total protein
Standard Curve Range: 0.75 to 150 fmol/µg of total protein
Custom Code: 3822000000
UNSPSC code: 41116104

Ohtsuki S., Uchida Y., Kubo Y., Terasaki T., Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: Methodology, advantages, strategy, and prospects, J. Pharm. Sci., 100: 3547–3559 (2011).

Kamiie J., Ohtsuki S., Iwase R., Ohmine K., Katsukura Y., Yanai K., Sekine Y., Uchida Y., Ito S., Terasaki T., Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res., 25: 1469-1483 (2008).

Sakamoto A., Matsumaru T., Ishiguro N., Schaefer O., Ohtsuki S., Inoue T., Kawakami H., Terasaki T., Reliability and robustness of simultaneous absolute quantification of drug transporters, cytochrome P450 enzymes, and Udp-Glucuronosyltranferases in human liver tissue by multiplexed MRM/selected reaction monitoring mode tandem mass spectrometer with nano-liquid chromatography, J. Pharm. Sci., 100: 4037–4043 (2011).

Kawakami H., Ohtsuki S., Kamiie J., Suzuki T., Abe T., Terasaki T., Simultaneous Absolute Quantifi cation of 11 Cytochrome P450 Isoforms in Human Liver Microsomes by Liquid Chromatography Tandem Mass Spectrometry with In Silico Target Peptide Selection, J. Pharm. Sci., 100: 341–352 (2011).

Ohtsuki S., Schaefer O., Kawakami H., Inoue T., Liehner S., Sato A., Ishiguro N., Kishimoto W., Ludwig-Schwellinger E., Ebner T., and Terasaki T., Simultaneous absolute protein quantifi cation of transporters, Cytochrome P450s and UDP glucuronosyltransferases as a

novel approach for the characterization of individual human liver: Comparison with mRNA levels and activities. Drug Metab. Dispos., 40(1):83-92 (2012)

Shawahna R., Uchida Y., Decleves X., Ohtsuki S., Yousif S., Dauchy S., Jacob A., Chassoux F., Daumas C., Couraud PO., Terasaki T., Scherrmann JM., Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm., 8: 1332-1341 (2011).

Uchida Y., Ohtsuki S., Kamiie J., Terasaki T., Blood-Brain Barrier (BBB) Pharmacoproteomics (PPx): Reconstruction of In Vivo Brain Distribution of 11 Pglycoprotein Substrates based on the BBB Transporter Protein Concentration, In Vitro Intrinsic Transport Activity, and Unbound Fraction in Plasma and Brain in Mice J. Pharmacol. Exp. Ther., 339: 579-588 (2011).

MS2Plex® is a brand name of Bertin Bioreagent.
MS2Plex® comes from an original technology, developed by Professor Tetsuya Terasaki from Tohoku University, Sendai, Japan. MS2Plex® is a significant breakthrough in membrane protein analysis. This Quantitative Targeted Absolute Proteomics (QTAP) is based on the identification and separation of protein digests by liquid chromatography linked tandem mass spectrometry with multiple reaction monitoring. Bertin Bioreagent has signed a worldwide exclusive license for this patented technology.

To better serve you, we aim to design our products and reagents to address your needs on the expected performance in terms of a possible range of use, but also on operational conditions of use & regulations. Thanks to our production processes and quality controls, we provide you with products with compliance to specifications.
Our technical support & science teams are available to help you assess their relevance depending on your needs, to specify the conditions of application and their fields of use. Finally, our researchers are ready to provide you with the necessary support by going, if needed, in your laboratories to validate your operating conditions and to solve possible problems.

/ We also advise you

Cross selling for this product : CYP2B6 (human) MS2Plex® assay kit There are 10 products.